GlobeNewswire by notified

One step closer to interoperability: Applying SNOMED CT’s engine to the International Patient Summary

Share

In 2022, SNOMED International will extend the core of SNOMED CT’s structured clinical terminology to deliver an open, standalone sub-ontology to support the scope of content within the International Patient Summary (IPS) under a Creative Commons license.

London, United Kingdom, Nov. 25, 2021 (GLOBE NEWSWIRE) -- At SNOMED International’s recent October Business Meetings held in London, the organization’s governance bodies enacted a decision to extend the core of SNOMED CT’s structured clinical terminology to deliver an open, standalone sub-ontology to support the scope of content within the International Patient Summary (IPS.)

The IPS is an electronic health record extract containing essential healthcare information for use in the unscheduled, cross-border care scenario, as well as for local, regional and other care scenarios. It is a minimal, non-exhaustive set of data elements defined by ISO/EN 17269 and delivered by HL7 in both CDA and FHIR using a curated set of SNOMED CT terms.

There is a groundswell of support across all health sectors to increase the portability and usability of patient information for the purpose of safe health care delivery. In 2019, SNOMED International and HL7 International announced the formalization of a license agreement in which a relevant ‘Free for Use’ Set of SNOMED CT coded concepts would be used within the HL7 IPS. Most recently, we watched as G7 leaders collaborated to release a communique on the dire need to progress a global health interoperability agenda. IBM offers a working definition of interoperability as “the timely and secure access, integration and use of electronic health data so that it can be used to optimize health outcomes for individuals and populations.”  The G7 communique, which highlighted the importance of enabling digital healthcare systems worldwide to work together seamlessly as patients move between providers, facilities and even countries, is an impactful statement that rippled throughout the global health community. A charge taken up by the Global Digital Health Partnership, it is one SNOMED International is eager to support.

Embracing a collaborative approach, “SNOMED International has been pleased to continue to work with HL7 International and partners across Europe and beyond to define SNOMED CT content for use in the International Patient Summary,” offered SNOMED International Management Board Chair, Joanne Burns.

Continuing to act in the spirit of the IPS Freeset, SNOMED International has committed to create and release an openly available IPS sub-ontology in the first half of 2022 to enhance the existing cross border movement of information, and ultimately health system interoperability. Unlike SNOMED International’s Global Patient Set, a flat list of SNOMED CT codes and terms, an IPS sub-ontology will provide implementers with a product that can be used in healthcare solutions using the power of SNOMED CT through its query language and hierarchies for the specified scope. Use of the IPS sub-ontology will allow for more effective use of clinical data analytics and decision support, and for Artificial Intelligence applications.

Alex Elias, Chair of SNOMED International’s General Assembly, the organization’s Member governance body, has observed a significant increase in discussion regarding the IPS. “2021 has seen increased interest by governments and Health and Care organizations globally for implementing the IPS to enhance timely cross border health information flow and interoperability. This has been a primary driver in SNOMED International supporting this recent initiative to make the IPS sub-ontology openly available with SNOMED CT content.“

An organization with an extensive history and active program of collaboration, SNOMED International CEO, Don Sweete, has played a pivotal role in positioning the IPS sub-ontology as a ‘soon to be achieved’ reality. “As the G7 Health Ministers recently indicated, the importance of enabling digital healthcare systems worldwide to work together seamlessly so patients don’t suffer as they move between providers, facilities and even countries is a sentiment that has rippled throughout the global health community”, offered Sweete. He went on to state that, “continued work with fellow health standards development, national, clinical and technical entities, SNOMED International will dedicate resources to achieve the goal of digital health interoperability.” Sweete added, “equipping the IPS, already one of the best examples of international collaboration among standards bodies, with the full capability of SNOMED CT’s ontological design is a significant action that we can contribute to achieving health information access gains for patients.”

Over the coming months, SNOMED International is formalizing the steps and due diligence required to make the IPS sub-ontology available for broad release. Throughout this period, SNOMED International will continue to define the IPS sub-ontology, from content through to its release and maintenance approach for launch in the first half of 2022.

Visit SNOMED International's IPS Sub-Ontology information page or subscribe to the organization’s news service to learn more as this initiative progresses. For additional information, contact info@snomed.org.

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

www.snomed.org

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Equinor vil starte andre transje av tilbakekjøpsprogrammet for aksjer for 202425.4.2024 06:47:33 CEST | Pressemelding

Equinor (OSE: EQNR, NYSE: EQNR) vil etter generalforsamlingen 14. mai 2024 starte andre transje av tilbakekjøpsprogrammet for aksjer for 2024 på inntil 1,6 milliarder USD, som annonsert i forbindelse med selskapets første kvartalsresultat 25. april 2024. Gjennomføring av tilbakekjøp i denne andre transjen er betinget av fornyet styrefullmakt fra generalforsamlingen den 14. mai 2024 og avtale med den norske stat om tilbakekjøp av aksjer. I denne andre transjen av tilbakekjøpsprogrammet for 2024 vil aksjer for inntil 528 millioner USD bli kjøpt i markedet, noe som vil gi en samlet andre transje på inntil 1,6 milliarder USD inkludert aksjer som skal innløses fra den norske stat. Transjen vil avsluttes senest 22. juli 2024. Equinor annonserte på kapitalmarkedsdagen i februar 2024 et toårig tilbakekjøpsprogram for aksjer på totalt 10-12 milliarder USD for 2024-2025, hvorav inntil 6 milliarder USD for 2024, inkludert aksjer som skal innløses fra den norske stat. Tilbakekjøpsprogrammet vil væ

Equinor to commence second tranche of the 2024 share buy-back programme25.4.2024 06:47:33 CEST | Press release

Equinor (OSE: EQNR, NYSE: EQNR) will after the annual general meeting 14 May 2024 commence the second tranche of up to USD 1.6 billion of the share buy-back programme for 2024, as announced in relation with the first quarter results 25 April 2024. Execution of share buy-back under this second tranche is subject to renewal of a board authorisation for share buy-back from the annual general meeting 14 May 2024 and agreement with the Norwegian State regarding share buy-back. In this second tranche of the share buy-back programme for 2024, shares for up to USD 528 million will be purchased in the market, implying a total second tranche of up to USD 1.6 billion including shares to be redeemed from the Norwegian State. The tranche will end no later than 22 July 2024. Equinor announced at the Capital Market Update in February 2024 a two-year share buy-back programme of total USD 10-12 billion for 2024-2025, with up to USD 6 billion for 2024, including shares to be redeemed from the Norwegian

Equinor ASA: Nøkkelinformasjon ved kontantutbytte for første kvartal 202425.4.2024 06:46:29 CEST | Pressemelding

Nøkkelinformasjon ved kontantutbytte for Equinor (OSE: EQNR, NYSE: EQNR) for første kvartal 2024. Ordinært utbyttebeløp: 0,35 Ekstraordinært utbyttebeløp: 0,35 Annonsert valuta: USD Siste dag inklusive: 15. august 2024 Ex-dato Oslo Børs: 16. august 2024 Ex-dato New York Stock Exchange: 19. august 2024 Record date (eierregisterdato): 19. august 2024 Betalingsdato: 28. august 2024 Vedtaksdato: 24. april 2024 Øvrig informasjon: Kontantutbytte i NOK per aksje vil bli kommunisert 23. august 2024. Denne informasjonen offentliggjøres i henhold til kravene i Løpende forpliktelser og er informasjonspliktig i henhold til verdipapirhandelloven §5-12.

Equinor ASA: Key information relating to cash dividend for first quarter 202425.4.2024 06:46:29 CEST | Press release

Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2024. Ordinary cash dividend amount: 0.35 Extraordinary cash dividend amount: 0.35 Announced currency: USD Last day including rights: 15 August 2024 Ex-date Oslo Børs: 16 August 2024 Ex-date New York Stock Exchange: 19 August 2024 Record date: 19 August 2024 Payment date: 28 August 2024 Date of approval: 24 April 2024 Other information: The cash dividend per share in NOK will be communicated 23 August 2024. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

Equinors resultater for første kvartal 202425.4.2024 06:45:00 CEST | Pressemelding

Equinor (OSE: EQNR, NYSE: EQNR) leverte et justert driftsresultat* på 7,53 milliarder USD, og 2,57 milliarder USD etter skatt i første kvartal 2024. Det rapporterte driftsresultatet var 7,63 milliarder USD, og resultatet for perioden var 2,67 milliarder USD. Justert resultat* var 2,84 milliarder USD, noe som ga et justert resultat per aksje* på 0,96 USD. Finansielle resultater og drift God drift og høy produksjonSolide finansielle resultater og kontantstrømSterke resultater fra tradingvirksomheten Strategisk framgang Kraft fra land til Sleipner- og Gudrun-feltene på norsk sokkelNy kraftsalgsavtale tildelt Empire Wind 1Forbedret gassportefølje på land i USA gjennom transaksjon Konkurransedyktig kapitaldistribusjon Ordinært kontantutbytte på 0,35 USD per aksjeFortsatt ekstraordinært kontantutbytte på 0,35 USD per aksje. Andre transje i tilbakekjøpsprogrammet på inntil 1,6 milliarder USDForventet total kapitaldistribusjon i 2024 på 14 milliarder USD. Anders Opedal, konsernsjef i Equinor A

HiddenA line styled icon from Orion Icon Library.Eye